In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Heart failure in women: insights from de RECOLFACA registry

Session Poster Session 1

Speaker Clara Ines Saldarriaga

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : CI Saldarriaga (Medellin,CO), JE Gomez (Cali,CO), LE Echeverria (Bucaramanga,CO)

Authors:
CI Saldarriaga1 , JE Gomez2 , LE Echeverria3 , 1Cardiovascular Clinic Santa Maria, Universityof Antioquia cardiology department - Medellin - Colombia , 2Valle del Lili Foundation, cardiology - Cali - Colombia , 3Fundacion cardiovascular , Heart failure - Bucaramanga - Colombia ,

On behalf: RECOLFACA registry

Citation:

Background:

There is a lack of information about heart failure in Latino America, the main objective of this registry was to characterize the population of  outpatients with heart failure that were followed in  60 Colombian hospitals in order to establish the differences between women and man in clinical presentation, comorbidities, treatment and quality of life.

Methods: This a cross-sectional analysis of HF in the Colombian Registry ( RECOLFACA) Continuous variables are expressed as mean (standard deviation) and categorical variables such as absolute values and proportions. T-student and Chi-square or Fisher test were used to identify differences between groups (Women vs men).

Results: 2099 patients were included from 2016 to 2018,mean age was 67.59 +/- 13.54 years, 43.46% were women. The main differences between men and women are presented in table 1.

CONCLUSIONS:

The data from RECOLFACA registry found significant differences according to sex, , women have more HFpEF, more anaemia and less chronic kidney disease. ACE inhibitors, ARB and MRA  were used  less often in women despite a similar use of beta-blockers and ARNI. There were no differences in the quality of life and NYHA functional class.

Variable

Women

Men

P value

HFrEF

63.6%

70.1%

0.001

HFpEF

19.7%

11.9%

0,001

HFmEF

16.6%

18%

0.001

NYHA I

10.5%

11.5%

0.472

NYHA II

56.4%

55.2%

0.472

NYHA III

26.2%

27.8%

0.472

NYHA IV

5.7%

3.9%

0.472

Anemia

38.9%

23.0%

0.000

CKD GFR< 60 ml/min

26.9%

73.4%

0.000

Quality of life

SPF 36 score

78.4

80.4

0.098

Ace inhibitors

28.8%

37.6%

0.001

ARB blockers

45%

36.5%

0.003

ARNI

10.3%

11.7%

0.49

Betablockers

84.3%

87.4%

0.124

MRA

49.6%

55.5%

0.003

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are